FTSE 100: 2 stocks to buy in a market slump

With fears of a market crash, I think buying the dip is the way to go. These two FTSE 100 shares are on my watchlist if it happens.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 index dipped below the 7,000 mark on Friday and hit a six-week low. Traders are bracing for a market crash and I feel that a slump over the next few weeks is likely. But, I also know that the FTSE 100 index is very resistant and can bounce back quickly if this is the case. At the moment, a dip in the market looks like an opportunity to invest in FTSE 100 stocks at a cut-price for my portfolio. Here I take a look at two tested shares that I think are poised for growth despite the unsteady market climate.

Pharma boom

AstraZeneca (LSE:AZN) was a big winner during the pandemic. Its vaccine, developed alongside Oxford University, was released at a price cheaper than the Pfizer and Moderna counterparts. But, the pharma giant is more than just a vaccine manufacturer.

AstraZeneca is at the forefront of medical R&D in fields like Oncology, cardiovascular, metabolic, and respiratory disease. Excluding the contribution from the Covid vaccine, revenue increased by 14% to $14.3bn in the first half (H1) of 2021. New medicines accounted for 54% of the total revenue with their sales growing 31% in the H1 2021 to $8.3bn.

I think that a global presence acts as a safety net in unsteady economic times. AstraZeneca’s revenue from emerging markets grew 35%, which is a really positive sign for me as a potential investor. Sales in China grew 21% to $3.2bn. The company also showed strong growth in Latin America, Middle East and Africa.

But the pharma sector poses some uncertainties. Drug patents expire quickly, allowing generic variants to flood the market. With a high portion of sales coming from new medicine, AstraZeneca is susceptible to losing sales to cheaper alternatives in the future. Also, medicine export is strictly controlled by national bodies and licenses can be cancelled at any time, which could impact revenue.

However, AstraZeneca’s track record and consistent R&D makes it a must-have FTSE 100 stock for my long-term portfolio. Its share price is down 5.1% in the last month but I would still wait for signs of a market crash before I invest.

Reemergence of elective healthcare

I am very bullish on pharma and healthcare stock at the moment. Elective healthcare procedures are making a comeback and Smith & Nephew (LSE: SN) stock could benefit.

Smith & Nephew specialises in orthopaedic surgery equipment and surgical devices. As hospitals worldwide recover from the pandemic, non-essential procedures are making a comeback. The company’s financials reflect this as well.

In H1 2021, revenue grew 21.3% (from H1 2020) to $2.6bn with a trading profit of $459m. The second quarter of 2021 showed a 40.3% jump in revenue compared to the same period in 2020. This shows me that the company has recovered well from the impact of the pandemic.

The firm is targeting revenue growth of 10%-13% in 2021 with a margin of 18%. With global surgical activity normalising, I think this is a realistic projection. 

This growth could halt if there is another virus breakout, which remains a concern. But, the recovery looks steady and I think the company’s market performance will reflect this. Also, this FTSE 100 stock is down 7.4% in the last month and a stock market crash could drive prices lower, presenting an excellent buying option for my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Suraj Radhakrishnan has no position in any of the shares mentioned. The Motley Fool UK has recommended Smith & Nephew. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »